DRAK2 Antibody (PA5-19927)

Performance guaranteed

Purchase with confidence, knowing that we stand behind
the performance of our antibodies with the InvitrogenTM
antibody performance guarantee. If an InvitrogenTM antibody
doesn't perform in your experiment as described on our website
or datasheet, we'll replace the product at no cost to you, or
if you prefer, we'll provide you with a credit for a future
purchase.*
Learn more.

Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C

Tested Applications

Dilution *

Immunocytochemistry (ICC)

10 µg/ml

Western Blot (WB)

0.5 µg/ml

* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the
product for use in their own experiment using appropriate negative and positive controls.

Product Specific Information

In Western blot applications, this antibody detects a band at ~45kDa. A suggested positive control is Jurkat cell lysate.

PA5-19927 can be used with blocking peptide PEP-0052.

Background/Target Information

Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases). DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.